Middle East and Africa Hematology Market Report

Middle East and Africa Hematology Market Size

The Middle East and Africa Western blotting market was valued at USD 113.92 million in 2024, is estimated to reach USD 115.98 million in 2025, and is projected to reach USD 133.88 million by 2033, growing at a CAGR of 1.81% from 2025 to 2033.

Western blotting has been utilized in the pharmaceutical, biopharmaceutical, and biotechnology industries for disease diagnosis, biomedical and biochemical research, food and beverage, agricultural, and quality control testing. Due to the rising incidence of diseases in the Middle East and Africa, western blot techniques are rapidly increasing.

The Middle East and Africa market for western blotting systems is growing due to the UAE's and Kuwait's strong economic development. Because AIDS is concentrated in a few countries, raising awareness about the implications of unsafe sexual behavior, particularly among high-risk groups, is the most effective strategy for combating the illness. Increased efforts and funding in research and the ever-expanding usage of western blotting in the field of proteomics & development by various pharmaceutical and biotechnology companies are all significant factors driving the growth of the western blotting market.

In the United Arab Emirates, marginalization and social stigma associated with AIDS and people thought to be at high risk of contracting the disease have hampered efforts to prevent HIV. In the Middle East and Africa, lack of public awareness and the high cost of therapy are limiting concerns; people cannot travel from remote locations. In addition, the shortage of qualified professional doctors to treat patients in remote places impedes the growth of the MEA western blotting market.

Geographically, MEA western blotting market had a moderate share in the global market in 2020. As the incidence of HIV diagnoses among people aged 15 to 29 climbs, the market for western blotting in the UAE is rising. However, Kuwait's traditional lifestyle, combined with the country's dire legal environment, is stifling demand for western technology systems.

Companies like Bio-Rad, Thermo Fisher Scientific, and others are active. Due to the adaptable nature of the population to novel products or technologies, companies can establish their novel product launches in the UAE, which is assisting the market studied to grow in this region.

KEY MARKET PLAYERS

Countries that are playing a prominent role in the MEA Western blotting market profiled in the report are Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., GE Healthcare, Advansta, Inc., LI-COR Biosciences, PerkinElmer Inc., Bio-Techne Corporation, Merck KGaA, F. Hoffmann-La Roche Ltd., and Cell Signaling Technology.

MARKET SEGMENTATION

This research report on the MEA western blotting market has been segmented and sub-segmented into the following categories.

By Product

• Instruments
• Consumables

By Application

• Biomedical & Biochemical Research
• Disease Diagnostics

By End User

• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies

By Country

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA